LAKE FOREST, Calif., April 21, 2015 /PRNewswire/ -- Cryoport, Inc. (OTCBB: CYRX) ("Company"), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers and reproductive medicine, today announced that Dr. Mark W. Sawicki, Chief Commercial Officer, will present at the 3rd Annual BioLogistics Summit in San Francisco, CA on Wednesday, July 15th, 2015, at 2:15 p.m. PT. Dr. Sawicki will discuss advanced logistics for both clinical samples and commercial finished goods of emerging cell and gene therapies.
The BioLogistics Summit is focused on regulatory compliance and quality operations and logistics for temperature-sensitive biologic materials and products for clinical and commercial supply chains. Many organizations strive to remain compliant with current GDP guidelines and struggle to efficiently anticipate forthcoming standards for the transportation of biologics on clinical and commercial supply chains. The Summit helps companies remain informed to accurately address domestic and international temperature-sensitive specialty supply chain challenges.
Dr. Mark Sawicki, Cryoport's Chief Commercial Officer, commented, "We are excited to participate in the 3rd Annual BioLogistics Summit, as it focuses on all of the drivers for our advanced cryogenic logistics solutions. The industry faces many challenges as organizations improve existing operations to streamline clinical trials or bring finished product to market under an ever stricter regulatory environment. Cryoport's globally validated cryogenic logistics solutions mitigate a company's concern for quality control and costly delays with a best-in-class network and chain-of-command capabilities."
A copy of the presentation will be accessible via the Resources section of the Company's website at www.cryoport.com for 60 days after the presentation.
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO's, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150 degrees C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world's largest shipping companies controlling more than 85% of the world's air shipments. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
SOURCE Cryoport, Inc.